Ken Griffin Exagen Inc. Call Options Transaction History

Citadel Advisors LLC

6 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$1.74 - $3.42 $3,480 - $6,840	2,000 Added 80.0%	4,500 $13,000
Q2 2024 Aug 14, 2024	BUY	$1.36 - $2.05 $1,224 - $1,844	900 Added 56.25%	2,500 $4,000
Q1 2024 May 15, 2024	BUY	$1.42 - $2.3 $2,130 - $3,449	1,500 Added 1500.0%	1,600 $2,000
Q4 2023 Feb 14, 2024	BUY	$1.45 - $2.39 $145 - $239	100 New	100 $0
Q1 2023 May 15, 2023	BUY	$2.23 - $2.9 $10,704 - $13,920	4,800 New	4,800 $11,000
Q3 2022 Nov 14, 2022	SELL	$2.69 - $8.68 $96,840 - $312,480	-36,000 Reduced 27.38%	95,500 $259,000

6.41M

4.5K

400

Ticker XGN
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 16,260,400
Market Cap $76.6M
Description
Exagen Inc. develops and commercializes various testing products based on its cell-bound complement activation products technology under the AVISE brand in the United States. It enables rheumatologists to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus ery...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.